Get the Stockscreener App
0.00
100.00%
-16.50
Invizyne Technologies Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Invizyne Technologies Inc is redefining biomanufacturing by leveraging cell-free multi-step enzyme-based systems to efficiently transform natural or renewable resources into highly sought-after chemicals. It believes that its biomanufacturing platform, known as SimplePath, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. its objective with SimplePath is to enable the efficient production of a diverse range of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform consists of a series of modular cascading enzyme-based biomanufacturing systems that leverage natural processes to perform complex chemical conversions.
See More
Previous Close:
$16.50
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$159.70M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$23.00
Invizyne Technologies Inc Stock (IZTC) Company Profile
Name
Invizyne Technologies Inc
Sector
Industry
Phone
(626) - 415 - 1488
Address
750 ROYAL OAKS DR, MONROVIA
Compare IZTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IZTC
Invizyne Technologies Inc
|
0.00 | 159.70M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.95 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.19 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.89 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.97 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.47 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Invizyne Technologies Inc Stock (IZTC) Latest News
Comparing Invizyne Technologies (NASDAQ:IZTC) and Caribou Biosciences (NASDAQ:CRBU) - Defense World
Invizyne Technologies Inc.’s (NASDAQ:IZTC) Lock-Up Period Set To Expire on May 12th - Defense World
Geode Capital Management LLC Makes New Investment in Invizyne Technologies Inc. (NASDAQ:IZTC) - Defense World
Bringing clarity and precision to the cell-free space by introducing exozymes - markets.businessinsider.com
Head-To-Head Contrast: iTeos Therapeutics (NASDAQ:ITOS) & Invizyne Technologies (NASDAQ:IZTC) - Defense World
EXoZymes Inc. Announces Its Latest Initiative BioClick - MarketScreener
Contrasting Invizyne Technologies (NASDAQ:IZTC) and C4 Therapeutics (NASDAQ:CCCC) - Defense World
EXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - MarketScreener
EXoZymes, Inc. Announces Management Changes -February 21, 2025 at 04:37 pm EST - Marketscreener.com
ExoZymes Inc. appoints new board member and chairman By Investing.com - Investing.com Australia
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - The Manila Times
eXoZymes Inc. Announces Leadership Changes and Rebranding Following Transition from Invizyne Technologies - Nasdaq
EXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering - Marketscreener.com
Can This AI-Powered Enzyme Company Transform the Future of Biotech? Nasdaq's Newest IPO Makes Bold Claims - StockTitan
Positive week for Invizyne Technologies, Inc. (NASDAQ:EXOZ) institutional investors who control 42% of the company - Simply Wall St
Institutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC) - Yahoo Finance UK
Invizyne Technologies, Inc. will Change its Name to eXoZymes, Inc -February 12, 2025 at 12:00 am EST - Marketscreener.com
Invizyne Technologies, Inc. will Change its Ticker to EXOZ from IZTC -February 12, 2025 at 12:00 am EST - Marketscreener.com
What’s in a Name: Out with Invizyne, In with eXoZymes - Genetic Engineering & Biotechnology News
Rebranding Invizyne to eXoZymes Signifies a Sustainable - GlobeNewswire
Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging - EIN News
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ - MSN
Invizyne announces corporate name change to eXoZymes - MSN
Invizyne Technologies Announces Name Change To EXoZymes - Nasdaq
MDBHMDB Capital Holdings LLC-A Latest Stock News & Market Updates - StockTitan
Invizyne Technologies Changes Name to eXoZymes -February 10, 2025 at 11:31 am EST - Marketscreener.com
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ By Investing.com - Investing.com Nigeria
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol - GlobeNewswire
Major Biotech Rebrand: Invizyne Becomes eXoZymesStrategic Move in Enzyme Manufacturing Space - Stock Titan
Invizyne technologies CEO Michael Heltzen buys $20,345 in stock - MSN
Invizyne technologies CEO Michael Heltzen buys $20,345 in stock By Investing.com - Investing.com Australia
Investors on Edge! What Invizyne’s Market Entry Means for Biotech’s Future - Jomfruland.net
Invizyne Technologies Inc.'s (NASDAQ:IZTC) Quiet Period To End on December 23rd - MarketBeat
Invizyne Technologies Inc.’s Quiet Period Set To Expire on December 23rd (NASDAQ:IZTC) - Defense World
Invizyne Technologies selected for $2 million project to advance SAF capabilities - Biomass Magazine
Invizyne Technologies Inc trading halted, volatility trading pause - TipRanks
Invizyne Technologies Inc trading resumes - Nasdaq
MDB Capital Holdings Provides Third Quarter 2024 Update - Marketscreener.com
Invizyne Technologies (IZTC) Income Statement & Balance Sheet 2024 - MarketBeat
MDB Capital Q3: Mayo Clinic Deal, AUM Surges to $28M, Invizyne IPO Success - StockTitan
Opening Day: Invizyne Technologies jumps after IPO - MSN
Invizyne technologies CEO acquires shares worth $22,022 By Investing.com - Investing.com Australia
Invizyne technologies CEO acquires shares worth $22,022 - Investing.com
Faculty in the News – James Bowie - UCLA – Chemistry and Biochemistry
Invizyne Technologies Inc Stock (IZTC) Financials Data
There is no financial data for Invizyne Technologies Inc (IZTC). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Invizyne Technologies Inc Stock (IZTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Heltzen Michael | Chief Executive Officer |
Jan 16 '25 |
Buy |
10.72 |
121 |
1,297 |
2,105 |
| Heltzen Michael | Chief Executive Officer |
Nov 15 '24 |
Buy |
11.10 |
1,984 |
22,022 |
1,984 |
0.91%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):